StockData
Nkarta, Inc. logo

Nkarta, Inc. (NKTX) stock

NKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$1.25+0.04 (+3.31%)

Close on Nov 17, 2026Market cap $89.53MP/E –Yield 0.00%

Nkarta r&d expenses

Research and development expenses are spending on new products and technology.

Nkarta's R&D Expenses for the twelve months ending Jun 30, 2026 was $99.51M, up 6.6% year over year. For fiscal 2025 it was $90.43M, down 6.5% from the year before. The highest annual figure on record is $96.77M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$90.43M-6.5%
FY2024Dec 31, 2024$96.74M-0.0%
FY2023Dec 31, 2023$96.77M+6.5%
FY2022Dec 31, 2022$90.90M+43.3%
FY2021Dec 31, 2021$63.41M+75.1%
FY2020Dec 31, 2020$36.22M+110.4%
FY2019Dec 31, 2019$17.22M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$29.05M+39.8%
Q1 FY2026Mar 31, 2026$24.99M+3.4%
Q4 FY2025Dec 31, 2025$25.28M+9.3%
Q3 FY2025Sep 30, 2025$20.20M-20.0%
Q2 FY2025Jun 30, 2025$20.78M-10.2%
Q1 FY2025Mar 31, 2025$24.17M-4.2%
Q4 FY2024Dec 31, 2024$23.13M-0.8%
Q3 FY2024Sep 30, 2024$25.25M+13.8%
Q2 FY2024Jun 30, 2024$23.13M-7.9%
Q1 FY2024Mar 31, 2024$25.24M-3.4%
Q4 FY2023Dec 31, 2023$23.32M-13.1%
Q3 FY2023Sep 30, 2023$22.19M-5.3%
Q2 FY2023Jun 30, 2023$25.12M+19.4%
Q1 FY2023Mar 31, 2023$26.14M+33.6%
Q4 FY2022Dec 31, 2022$26.84M+55.2%
Q3 FY2022Sep 30, 2022$23.44M+41.0%
Q2 FY2022Jun 30, 2022$21.05M+31.9%
Q1 FY2022Mar 31, 2022$19.57M+44.5%
Q4 FY2021Dec 31, 2021$17.30M+53.5%
Q3 FY2021Sep 30, 2021$16.62M+69.1%
Q2 FY2021Jun 30, 2021$15.96M+103.0%
Q1 FY2021Mar 31, 2021$13.54M+86.5%
Q4 FY2020Dec 31, 2020$11.27M+68.7%
Q3 FY2020Sep 30, 2020$9.83M+112.7%
Q2 FY2020Jun 30, 2020$7.86M+117.1%
Q1 FY2020Mar 31, 2020$7.26M–
Q4 FY2019Dec 31, 2019$6.68M–
Q3 FY2019Sep 30, 2019$4.62M–
Q2 FY2019Jun 30, 2019$3.62M–

More Nkarta figures

See a number that looks wrong?